Amgen Inc. has announced impressive financial results for 2025, with revenues of $36.75 billion and double-digit growth in both revenues and earnings per share. Looking ahead, the company projects 2026 revenues between $37.0 billion and $38.4 billion, alongside an expected 21.9% rise in earnings per share. As part of its sustainable payout strategy, Amgen has also increased its dividend to $2.52, despite potential market challenges from biosimilars and pricing pressures. Analysts view Amgen as an undervalued stock with strong comeback potential, evidenced by positive performance and rating upgrades.
“Amgen recently reported past fourth-quarter and full-year 2025 results showing higher revenues of US$9.87 billion for the quarter and US$36.75 billion for the year...”
“The new European approval for UPLIZNA enhances Amgen’s rare autoimmune footprint but does not fundamentally change the near term focus...”
“The 2026 guidance issued alongside Amgen’s strong 2025 results matters here. Management outlined expected total revenue of US$37.0 billion to US$38.4 billion and GAAP EPS of US$15.45 to US$16.94...”
“Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028...”
“Beyond Moderna, Yee identified several “comeback stories” that he finds compelling, including Merck, Bristol Myers Squibb, Amgen, and Gilead. He described these stocks as cheap relative to their potential and noted they are beginning to break out.”
“Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m. PT on Wednesday, Feb. 18, 2026.”
“Amgen Inc. (NASDAQ:AMGN) received rating updates from Argus Research and Guggenheim on February 6. Argus reiterated a Buy rating on the stock with a $400 price target, while Guggenheim reaffirmed a Hold rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $347.”
“Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q4 and full year 2025 results on February 3, announcing strong performance in 2025 with double-digit growth in revenues and EPS.”
“Amgen Inc. (NASDAQ:AMGN) expects total revenues in the $37.0 billion to $38.4 billion range for the full year 2026.”
“Why Are We Fans of AMGN? Solid 14.2% annual revenue growth over the last two years indicates its offering’s solve complex business issues.”
“$36.75 billion in revenue gives its scale, which leads to bargaining power with customers because there are few trusted alternatives.”
“Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends.”